- Home
- LYT vs ZVSA Comparison
LYT vs ZVSA Comparison
Compare LYT & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYT
- ZVSA
- Stock Information
- Founded
- LYT 2020
- ZVSA 2014
- Country
- LYT India
- ZVSA United States
- Employees
- LYT N/A
- ZVSA N/A
- Industry
- LYT EDP Services
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- LYT Technology
- ZVSA Health Care
- Exchange
- LYT Nasdaq
- ZVSA Nasdaq
- Market Cap
- LYT 1.8M
- ZVSA 1.5M
- IPO Year
- LYT 2022
- ZVSA N/A
- Fundamental
- Price
- LYT $0.72
- ZVSA $1.42
- Analyst Decision
- LYT
- ZVSA Strong Buy
- Analyst Count
- LYT 0
- ZVSA 1
- Target Price
- LYT N/A
- ZVSA $240.00
- AVG Volume (30 Days)
- LYT 4.4M
- ZVSA 2.2M
- Earning Date
- LYT 08-15-2024
- ZVSA 11-14-2024
- Dividend Yield
- LYT N/A
- ZVSA N/A
- EPS Growth
- LYT N/A
- ZVSA N/A
- EPS
- LYT 0.30
- ZVSA N/A
- Revenue
- LYT $21,363,775.00
- ZVSA N/A
- Revenue This Year
- LYT N/A
- ZVSA N/A
- Revenue Next Year
- LYT N/A
- ZVSA N/A
- P/E Ratio
- LYT $2.42
- ZVSA N/A
- Revenue Growth
- LYT 12.39
- ZVSA N/A
- 52 Week Low
- LYT $0.54
- ZVSA $0.98
- 52 Week High
- LYT $18.62
- ZVSA $25.00
- Technical
- Relative Strength Index (RSI)
- LYT 30.59
- ZVSA 57.25
- Support Level
- LYT $0.54
- ZVSA $1.31
- Resistance Level
- LYT $0.76
- ZVSA $1.95
- Average True Range (ATR)
- LYT 0.08
- ZVSA 0.19
- MACD
- LYT 0.01
- ZVSA 0.04
- Stochastic Oscillator
- LYT 40.91
- ZVSA 44.21
About LYT Lytus Technologies Holdings PTV. Ltd.
Lytus Technologies Holdings Pvt Ltd is a platform services company providing content streaming/telecasting services to users located all across India. Its scope of business also covers telemedicine services with local assistance through local Health Centers. Through its platform, the customers are well connected via customer premises equipment (CPE) devices/set-top boxes (STBs) and have access to multi-dimensional services including telemedicine service.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.